Marissa C. Jarosinski

Marissa C. Jarosinski

Auto-generated profile, based on publicly available information

Marissa C. Jarosinski

Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2024 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MJMarissa Jarosinski
Marissa Jarosinski
JKJason N. Kennedy
Jason N. Kennedy
YKYekaterina Khamzina
Yekaterina Khamzina
FAFanny S. Alie-Cusson
Fanny S. Alie-Cusson
ETEdith Tzeng
Edith Tzeng
KRKatherine M. Reitz
Katherine M. Reitz

26 July 2024 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
MJMarissa C. Jarosinski
Marissa C. Jarosinski
JKJason N. Kennedy
Jason N. Kennedy
SIStuthi Iyer
Stuthi Iyer
ETEdith Tzeng
Edith Tzeng
MEMohammad Eslami
Mohammad Eslami
KRKatherine M. Reitz
Katherine M. Reitz

27 August 2024 in Journal of Vascular Surgery
Verified
Journal Article
Open access
MJMarissa C. Jarosinski
Marissa C. Jarosinski
MHMuhammed S. Hafeez
Muhammed S. Hafeez
NSNatalie D. Sridharan
Natalie D. Sridharan
EAElizabeth A. Andraska
Elizabeth A. Andraska
JMJoseph M. Meyer
Joseph M. Meyer
KRKatherine M. Reitz
Katherine M. Reitz
Optimal medical therapy (OMT) is a modifiable factor that reduces mortality and cardiovascular events in patients with severe peripheral arterial disease. We hypothesized preintervention OMT would be associated with improved 1-year reintervention and major adverse limb event (MALE) rates following elective endovascular revascularization for intermittent claudication (IC). Using the Vascular Quality Initiative (2010-2020), we identified patients with IC undergoing elective endovascular, hybrid, and open surgical interventions. Preoperative antiplatelet, statin, and non-smoking status defined OMT components and created three groups: complete (all components), partial (1-2 components), and no OMT. The primary outcome was 1-year reintervention. Secondary outcomes included MALE and factors associated with OMT usage. Multivariable logistic regression generated adjusted odds ratios (aOR). 39,088 patients (14,907 [38.1%] complete, 22,054 [56.4%)] partial, 2,127 [5.4%] no OMT) met criteria. Patients with any OMT were more frequently older with more cardiovascular diseases and diabetes (p<0.0001). Patients without OMT were more likely to be Black or with Medicare/Medicaid (p<0.05). Observed 1-year reintervention (5.3% complete OMT, 6.1% partial OMT, 8.3% no OMT; p<0.001) and MALE (5.6% complete OMT, 6.3% partial OMT, 8.8% no OMT; p<0.001) were decreased by partial or complete OMT compared to no OMT. Complete OMT significantly reduced the adjusted odds of re-intervention and MALE by 28% (aOR=0.72, 95% confidence interval [95%CI] 0.59-0.88) and 30% (aOR=0.70, 95%CI 0.58-0.85), respectively, compared to no OMT. Partial OMT reduced the adjusted odds of re-intervention and MALE by 24% (aOR=0.76, 95%CI 0.63-0.92) and 26% (aOR=0.74, 95%CI 0.62-0.89), respectively. Preintervention OMT is an underutilized, modifiable risk factor associated with improved one-year reintervention and MALE. Vascular surgeons are uniquely positioned to initiate and maintain OMT in patients with IC prior to revascularization to optimize patient outcomes.

12 December 2023 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JDJack Kevin Donohue
Jack Kevin Donohue
MJMarissa Jarosinski
Marissa Jarosinski
KRKatherine M. Reitz
Katherine M. Reitz
YKYekaterina Khamzina
Yekaterina Khamzina
JLJonathan Ledyard
Jonathan Ledyard
NSNatalie D. Sridharan
Natalie D. Sridharan

31 March 2025 in Journal of Vascular Surgery
Verified
Journal Article
Open access
MJMarissa C. Jarosinski
Marissa C. Jarosinski
KLKevin Li
Kevin Li
EAElizabeth A. Andraska
Elizabeth A. Andraska
KRKatherine M. Reitz
Katherine M. Reitz
NLNathan L. Liang
Nathan L. Liang
NSNatalie D. Sridharan
Natalie D. Sridharan
Endovascular treatment of acute limb ischemia (ALI), primarily consisting of catheter-directed thrombolysis (CDT), has been shown to reduce mortality without affecting limb salvage. Percutaneous thrombectomy (PT) devices have expanded endovascular approaches while decreasing thrombolytic use. While many advocate for an endovascular-first approach, it's unclear which patients would benefit most from each strategy. We included adults (18+) who underwent revascularization for infrainguinal ALI (01/2016-12/2023) at a multihospital healthcare system. We compared amputation and mortality after endovascular vs. open approaches using logistic regression, Kaplan-Meier curves, and cox regression. We included 315 patients: 145 undergoing an endovascular-first strategy (89 CDT, 51 PT, 5 angioplasty/stent) and 170 undergoing open therapy (132 open thrombectomy, 38 bypass). Patients undergoing endovascular-first treatment were less ischemic, had more prior stenting, and more acute-on-chronic disease. Patients undergoing PT with suction devices were less likely to undergo overnight CDT compared to those with rheolytic devices (21% vs 67%, p=0.004). There were no differences in 30-day amputation or mortality, but 30-day reintervention was increased in the endovascular group (aOR=2.29 [1.06-4.91], p=0.03). 3-year amputation rates were not significantly different on univariable or multivariable analysis when comparing the endovascular-first approach to open. PT alone trended toward increased amputation rates compared to open (aHR=1.96, 95%CI 0.98-3.94, p=0.058), however, this was mainly driven by the use of rheolytic devices with an amputation rate of 64% vs. 8% in suction devices. Furthermore, those with embolic disease had significantly increased amputation rates (aHR=2.92 [1.29-6.58], p=0.01; pinteraction=0.02) with any endovascular-first strategy, when compared to open therapy. Endovascular-first patients had decreased mortality on univariable analysis (16% vs. 37%, log-rank=0.004) but not multivariable analysis (aHR=0.60 [0.32-1.13], p=0.12). When separated by endovascular modality, CDT had decreased mortality compared to open (aHR=0.41 [0.18-0.93], p=0.033), while PT did not (aHR=1.05 [0.47-2.35], p=0.91). While effect of treatment modality on outcomes was not moderated by Rutherford classification, only 22 patients underwent endovascular-first treatment for Rutherford 2b ischemia. Endovascular-first therapy had increased 3-year amputation in patients with embolic etiology of disease compared to open therapy. We also saw increased 30-day reintervention with endovascular-first therapy when compared to open therapy. CDT had decreased 3-year mortality when compared to open therapy. PT devices had mixed results, indicating that this is a technology in evolution. Newer PT devices are effective at reducing thrombolytic usage, and their amputation and mortality rates were similar to open therapy. An endovascular-first approach to Rutherford 2b ischemia needs further evaluation.

30 October 2024 in JVS-Vascular Insights
Verified
Journal Article
Open access
MJMarissa C. Jarosinski
Marissa C. Jarosinski
KRKatherine M. Reitz
Katherine M. Reitz
YKYekaterina Khamzina
Yekaterina Khamzina
NLNathan L. Liang
Nathan L. Liang
NSNatalie D. Sridharan
Natalie D. Sridharan
ETEdith Tzeng
Edith Tzeng
Antithrombotic therapy improves endovascular intervention outcomes for peripheral artery disease. However, there are limited data guiding the choice and duration of these adjuvant therapies. Thus, we explored current antithrombotic prescribing preferences among vascular interventionalists, hypothesizing that there are varied and inconsistent treatment practices among providers. We developed and distributed a de-identified RedCap survey via Twitter and email to Vascular Quality Initiative members (February 2023). Multiple-choice questions queried antithrombotic agents and treatment durations for a clinical vignette (a claudicant on 81 mg aspirin and statin) with different arterial disease locations (iliac, femoropopliteal, or tibial vessels) and different revascularization strategies (angioplasty or stenting, with and without drug-coating). Antithrombotic options included monotherapies with antiplatelet agents or low-dose rivaroxaban; dual therapies with aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) or low-dose rivaroxaban (dual pathway inhibition or DPI); or triple therapy with aspirin, a P2Y12 inhibitor, and low-dose rivaroxaban. Options for therapy duration included 30, 90, 180, and 365 days, or indefinitely. There were 199 respondents (17% female, 68% White race, 63% academic, 88% vascular surgery). Across all treatment scenarios, respondents selected DAPT (n = 171/199; 86%) in at least one revascularization scenario, followed by aspirin monotherapy (n = 83/199; 42%) and DPI (n = 49/199; 25%). Therapy choice did differ by both anatomic location and revascularization strategy (P < .05). DAPT was most selected following femoropopliteal revascularization (n = 165/199, 83%) and bare metal stenting (n = 162/198, 82%). However, aspirin monotherapy was most selected following iliac level revascularization (n = 52/197; 26%) and following percutaneous transluminal angioplasty at any level (n = 51/182; 28%). DPI was most selected following tibial revascularization (n = 39/184; 21%) and following percutaneous transluminal angioplasty (n = 38/182; 21%). Among those who selected DAPT, the 90-day (n = 99/171; 58%) duration was preferred. Those who selected DPI favored indefinite treatment durations (n = 34/49; 69%). Indefinite DAPT and DPI therapy were more commonly selected for distal level revascularization (P < .05). Rivaroxaban utilization was limited secondary to cost (n = 108/178; 61%), lack of demonstrated effectiveness (n = 75/178; 42%), and concern for safety and bleeding (n = 27/178; 15%). Following lower extremity endovascular treatment of peripheral artery disease, a 90-day duration of DAPT remains the most commonly selected antithrombotic regimen despite the emergence of DPI as an evidence-based antithrombotic therapy. The variability in provider preferred antithrombotic agent and treatment duration emphasizes the need for high-quality evidence for the medical optimization of revascularization outcomes.